Nephrology

Reports of high-impact nephrology studies by medical professionals

Lumasiran decreases urinary oxalate excretion in Primary Hyperoxaluria Type 1

1. Lumasiran was shown to decrease urinary oxalate excretion in patients with Primary Hyperoxaluria Type 1. 2. Lumasiran was shown not to cause severe or...

Prediction of individuals at high risk of chronic kidney disease during treatment with lithium...

1. Individuals with bipolar disorder at higher risk of chronic kidney disease after lithium initiation include patients who are young, female, obese, have high...

Vadadustat noninferior to darbepoetin for treating anemia in dialysis patients

1. Vadadustat was shown to be non-inferior to darbepoetin alfa in cardiovascular safety for patients with anemia and dialysis-dependent chronic kidney disease (DD-CKD). 2. Vadadustat...

Postponing renal replacement therapy may result in poor clinical outcomes in patients with severe...

1. The median number of RRT-free days was 12 days (IQR 0-25) in the delayed strategy and 10 days (IQR 0-24) in the more-delayed...

Initial effects of COVID-19 on patients with end-stage kidney disease

1. Patients with end-stage kidney disease were at increased risk of COVID-19-related mortality, particularly among non-Hispanic Black patients. Evidence Rating Level: 3 (Average) End-stage kidney disease...

Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment

1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib plus pembrolizumab demonstrated longer progression-free...

Direct oral anticoagulants may be the superior treatment for patients with atrial fibrillation on...

1. Direct oral anticoagulants may have a superior risk-benefit profile compared to vitamin K antagonists in atrial fibrillation for patients with hemodialysis. Evidence Rating Level:...

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment caused more drug discontinuation compared...

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). 2. Occurrence of grade 3...

Everolimus treatment effective for improving renal function in lung transplant patients

1. Lung transplant patients showed improved renal function and reduced immunosuppressant dosage after twelve months of everolimus treatment. 2. Patients with chronic lung allograft dysfunction...

All-time hits